Captor Therapeutics announces positive proof-of-concept efficacy in-vivo data for its lead CT-03 program with strong antitumor activity at all doses tested
Wroclaw, Poland, February 25, 2022 - Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, announces positive preclinical data with its lead program CT-03, highly potent MCL-1 degraders being developed in several cancer types. Captor’s first-in-class MCL-1-targeting degrader drugs have the potential to be used in the treatment of a number of haematological malignancies, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)
The new data were generated by an independent contract research organization which conducted multiple dose proof-of-concept efficacy experiments, which specifically monitored tumor volumes in mice implanted with human tumors of acute myeloid leukemia. The CT-03 compounds were tested at 75 mg/kg and at 150 mg/kg. The data generated demonstrate that once-a-day administration of CT-03 compounds resulted in a strong anticancer effect at both dose levels in the MV-4-11 mouse model of acute myeloid leukemia.
These new preclinical data are fully consistent with previously reported single dose study data on the pharmacological effects of CT-03, reported in September 2021. Together, these studies demonstrate that CT- 03 lead compounds cause the efficient degradation of the MCL-1 target in implanted human tumor cells, induce apoptosis in these cells, and as a result, cause the shrinkage or regression of the tumor.
These data support the further advancement of Captor’s candidates towards the next milestones of Candidate Selection and IND-enabling studies. Simultaneously, these results demonstrate the capability of the Company to rationally discover and optimize bifunctional degrader-type drug candidates using its OptigradeTM platform.
“The last few months have been transformative for Captor as we have generated very impressive preclinical data for both CT-01 and CT-03, positioning both as potential best-in-class and first-in-class compounds to tackle a large number of cancers with poor therapeutic options,” said Dr Tom Shepherd, Chief Executive Officer of Captor Therapeutics. “Thanks to the tireless efforts and great science delivered by Captor’s team, we remain on track to initiate clinical trials in 2023 with our two leading assets.”
About Captor Therapeutics
Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs. TPD is a revolutionary approach to developing new drugs that can address novel molecular targets which are deemed “undruggable” with classical drug development approaches, as well as providing additional treatment options for diseases where existing drugs fail to provide optimal medical benefit. Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.
More information on Captor Therapeutics is available at: http://www.captortherapeutics.com
For further information, please contact:
Polish Media and Investor relations:
Point of View
+48 694 400 787
International Investor Relations:
Guillaume van Renterghem
+41 (0)76 735 01 31